Celon Pharma (0RKX) Stock Overview

An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. More details

0RKX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 92.4% below our estimate of its fair value

Earnings are forecast to grow 16.74% per year

Risk Analysis

Shares are highly illiquid

0RKX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

4.3k

US$21.53

67.6% undervalued

stuart_roberts's

Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Celon Pharma S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Celon Pharma
Historical stock prices
Current Share Price	zł22.50
52 Week High	zł22.50
52 Week Low	zł22.50
Beta	0.85
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-39.22%

Recent updates

Shareholder Returns

	0RKX	GB Pharmaceuticals	GB Market
7D	0%	-1.1%	-0.5%
1Y	n/a	20.0%	19.4%

Return vs Industry: Insufficient data to determine how 0RKX performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 0RKX performed against the UK Market.

Price Volatility

Is 0RKX's price volatile compared to industry and market?
0RKX volatility
0RKX Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	5.1%
10% most volatile stocks in GB Market	11.6%
10% least volatile stocks in GB Market	2.8%

Stable Share Price: 0RKX's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0RKX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2002	567	Maciej Wieczorek	www.celonpharma.com

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.

Celon Pharma S.A. Fundamentals Summary

How do Celon Pharma's earnings and revenue compare to its market cap?
0RKX fundamental statistics
Market cap	zł1.22b
Earnings (TTM)	-zł43.86m
Revenue (TTM)	zł215.11m

5.7x

P/S Ratio

-27.9x

P/E Ratio

Is 0RKX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RKX income statement (TTM)
Revenue	zł215.11m
Cost of Revenue	zł69.38m
Gross Profit	zł145.73m
Other Expenses	zł189.59m
Earnings	-zł43.86m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Sep 17, 2025

Earnings per share (EPS)	-0.81
Gross Margin	67.75%
Net Profit Margin	-20.39%
Debt/Equity Ratio	1.1%

How did 0RKX perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

23%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/08/24 11:24
End of Day Share Price	2025/05/27 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celon Pharma S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamil Kliszcz	Biuro maklerskie mBanku
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku
Vladimira Urbankova	Erste Group Bank AG

Celon Pharma S.A.LSE:0RKX Stock Report